Linked Life Data

16210655

Source:http://linkedlifedata.com/resource/pubmed/id/16210655

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16210655rdf:typepubmed:Citationlld:pubmed
pubmed-article:16210655lifeskim:mentionsumls-concept:C0237798lld:lifeskim
pubmed-article:16210655lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:16210655lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:16210655lifeskim:mentionsumls-concept:C1823153lld:lifeskim
pubmed-article:16210655lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:16210655lifeskim:mentionsumls-concept:C1705241lld:lifeskim
pubmed-article:16210655lifeskim:mentionsumls-concept:C0439097lld:lifeskim
pubmed-article:16210655lifeskim:mentionsumls-concept:C2349976lld:lifeskim
pubmed-article:16210655lifeskim:mentionsumls-concept:C1552644lld:lifeskim
pubmed-article:16210655lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:16210655lifeskim:mentionsumls-concept:C1709630lld:lifeskim
pubmed-article:16210655lifeskim:mentionsumls-concept:C1547348lld:lifeskim
pubmed-article:16210655pubmed:issue8lld:pubmed
pubmed-article:16210655pubmed:dateCreated2005-10-7lld:pubmed
pubmed-article:16210655pubmed:abstractTextVgamma9Vdelta2(+) cells represent the major population of gammadelta T cells in primate blood and react in an MHC-unrestricted fashion to a set of low m.w. nonpeptide phosphoantigens. Two types of structurally related agonists have been discovered so far: the natural phosphoantigens (hydroxydimethyl allyl-pyrophosphate or isopentenyl-pyrophosphate (IPP)) acting directly on Vgamma9Vdelta2(+) TCR and aminobisphosphonates, which block the mevalonate pathway in target cells, leading to accumulation of natural phosphoantigens that in turn activate Vgamma9Vdelta2(+) cells. We demonstrate in the cynomolgus monkey that Vgamma9Vdelta2 can be manipulated in vivo with bromohydrin pyrophosphate (BrHPP)/Phosphostim, a potent synthetic agonist for which the mechanism of action is similar to natural phosphoantigens. Although of very short half-life, injection of BrHPP leads to strong activation of Vgamma9Vdelta2, inducing production of a high level of Th1 cytokines. Combination of BrHPP with low-dose rhIL-2 induces specific amplification of effector-memory peripheral Vgamma9Vdelta2 in blood in a dose-dependant manner. This transient response returns to baseline within 10-15 days. Successive infusions of BrHPP and rhIL-2 induce less vigorous expansions, suggesting a progressive exhaustion of the response. As no toxicity is detected with or without IL-2, this scheme represents a promising immunotherapeutic strategy for induction of systemic Th1 cytokines and massive expansion of gammadelta T cell subset with antitumor and anti-infectious properties.lld:pubmed
pubmed-article:16210655pubmed:languageenglld:pubmed
pubmed-article:16210655pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16210655pubmed:citationSubsetAIMlld:pubmed
pubmed-article:16210655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16210655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16210655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16210655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16210655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16210655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16210655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16210655pubmed:statusMEDLINElld:pubmed
pubmed-article:16210655pubmed:monthOctlld:pubmed
pubmed-article:16210655pubmed:issn0022-1767lld:pubmed
pubmed-article:16210655pubmed:authorpubmed-author:FourniéJean-J...lld:pubmed
pubmed-article:16210655pubmed:authorpubmed-author:BonnevilleMar...lld:pubmed
pubmed-article:16210655pubmed:authorpubmed-author:TiollierJérôm...lld:pubmed
pubmed-article:16210655pubmed:authorpubmed-author:RomagnéFranço...lld:pubmed
pubmed-article:16210655pubmed:authorpubmed-author:SicardHélèneHlld:pubmed
pubmed-article:16210655pubmed:authorpubmed-author:IngoureSophie...lld:pubmed
pubmed-article:16210655pubmed:authorpubmed-author:LucianiBéatri...lld:pubmed
pubmed-article:16210655pubmed:authorpubmed-author:SerrazClaireClld:pubmed
pubmed-article:16210655pubmed:issnTypePrintlld:pubmed
pubmed-article:16210655pubmed:day15lld:pubmed
pubmed-article:16210655pubmed:volume175lld:pubmed
pubmed-article:16210655pubmed:ownerNLMlld:pubmed
pubmed-article:16210655pubmed:authorsCompleteYlld:pubmed
pubmed-article:16210655pubmed:pagination5471-80lld:pubmed
pubmed-article:16210655pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:meshHeadingpubmed-meshheading:16210655...lld:pubmed
pubmed-article:16210655pubmed:year2005lld:pubmed
pubmed-article:16210655pubmed:articleTitleIn vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model.lld:pubmed
pubmed-article:16210655pubmed:affiliationInnate Pharma, Marseilles, France. sicard@innate-pharma.frlld:pubmed
pubmed-article:16210655pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16210655lld:pubmed